product summary
Loading...
company name :
Dianova
product type :
antibody
product name :
Anti-IDH1 R132H (Hu) from Mouse (Clone: H09)
catalog :
DIA-H09
quantity :
500 µl
price :
482 EUR plus VAT
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
H09
reactivity :
human
application :
western blot, immunohistochemistry, immunocytochemistry, immunohistochemistry - paraffin section
more info or order :
Dianova product webpage
citations: 39
Published Application/Species/Sample/DilutionReference
  • immunohistochemistry - paraffin section; human; loading ...; fig 2a
Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, et al. Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma. Neurosurgery. 2018;: pubmed publisher
  • immunohistochemistry; human; 1:50; loading ...; fig 2o
Ronellenfitsch M, Oh J, Satomi K, Sumi K, Harter P, Steinbach J, et al. CASP9 germline mutation in a family with multiple brain tumors. Brain Pathol. 2018;28:94-102 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:40; loading ...; tbl 1
Le Rhun E, Duhamel M, Wisztorski M, Gimeno J, Zairi F, Escande F, et al. Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification. Biochim Biophys Acta Proteins Proteom. 2017;1865:875-890 pubmed publisher
  • immunohistochemistry; human; loading ...; fig 1a
Hacisalihoglu P, Kucukodaci Z, Gundogdu G, Bilgic B. The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients. Turk Neurosurg. 2017;27:682-689 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:50; loading ...; tbl 1
Bielle F, Ducray F, Mokhtari K, Dehais C, Adle Biassette H, Carpentier C, et al. Tumor cells with neuronal intermediate progenitor features define a subgroup of 1p/19q co-deleted anaplastic gliomas. Brain Pathol. 2017;27:567-579 pubmed publisher
  • immunohistochemistry; human; loading ...; fig 3c
Oktay Y, Ãœlgen E, Can Ã, Akyerli C, Yüksel Å, Erdemgil Y, et al. IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. Sci Rep. 2016;6:27569 pubmed publisher
  • immunocytochemistry; human; 1:50; fig 2
  • western blot; human; 1:500; fig 9
Rosiak K, Smolarz M, Stec W, Peciak J, Grzela D, Winiecka Klimek M, et al. IDH1R132H in Neural Stem Cells: Differentiation Impaired by Increased Apoptosis. PLoS ONE. 2016;11:e0154726 pubmed publisher
  • immunohistochemistry; human; 1:20; loading ...; fig 1c
Casar Borota O, Øystese K, Sundstrom M, Melchior L, Popovic V. A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. Pituitary. 2016;19:407-14 pubmed publisher
  • immunohistochemistry; human; 1:40; tbl 2
Liang L, Olar A, Niu N, Jiang Y, Cheng W, Bian X, et al. Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. Am J Surg Pathol. 2016;40:847-56 pubmed publisher
  • western blot; human; 1:500; fig 6
Wille C, Nawandar D, Henning A, Ma S, Oetting K, Lee D, et al. 5-hydroxymethylation of the EBV genome regulates the latent to lytic switch. Proc Natl Acad Sci U S A. 2015;112:E7257-65 pubmed publisher
  • immunohistochemistry; human; 1:50; loading ...; tbl 1
Yamaguchi M, Komori T, Nakata Y, Yagishita A, Morino M, Isozaki E. Multinodular and vacuolating neuronal tumor affecting amygdala and hippocampus: A quasi-tumor?. Pathol Int. 2016;66:34-41 pubmed publisher
  • western blot; human
Liu Y, Gilbert M, Kyprianou N, Rangnekar V, Horbinski C. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol. 2014;128:723-32 pubmed publisher
Georgescu M, Olar A. Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma. Acta Neuropathol Commun. 2020;8:10 pubmed publisher
McBrayer S, Mayers J, DiNatale G, Shi D, Khanal J, Chakraborty A, et al. Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell. 2018;175:101-116.e25 pubmed publisher
Gao Y, de Wit M, Struys E, van der Linde H, Salomons G, Lamfers M, et al. IDH1-mutated transgenic zebrafish lines: An in-vivo model for drug screening and functional analysis. PLoS ONE. 2018;13:e0199737 pubmed publisher
Bieńkowski M, Wöhrer A, Moser P, Kitzwögerer M, Ricken G, Strobel T, et al. Molecular diagnostic testing of diffuse gliomas in the real-life setting: A practical approach. Clin Neuropathol. 2018;37:166-177 pubmed publisher
Wei S, Wang J, Oyinlade O, Ma D, Wang S, Kratz L, et al. Heterozygous IDH1R132H/WT created by "single base editing" inhibits human astroglial cell growth by downregulating YAP. Oncogene. 2018;37:5160-5174 pubmed publisher
Jiang B, Zhao W, Shi M, Zhang J, Chen A, Ma H, et al. IDH1 Arg-132 mutant promotes tumor formation through down-regulating p53. J Biol Chem. 2018;293:9747-9758 pubmed publisher
Masui K, Komori T, Kato Y, Masutomi K, Ichimura K, Ogasawara S, et al. Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody. Biomed Res Int. 2018;2018:7945845 pubmed publisher
Waitkus M, Pirozzi C, Moure C, Diplas B, Hansen L, Carpenter A, et al. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities. Cancer Res. 2018;78:36-50 pubmed publisher
Jalbert L, Elkhaled A, Phillips J, Neill E, Williams A, Crane J, et al. Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. Sci Rep. 2017;7:44792 pubmed publisher
Louis D, Perry A, Reifenberger G, von Deimling A, Figarella Branger D, Cavenee W, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803-20 pubmed publisher
Amelot A, De Cremoux P, Quillien V, Polivka M, Adle Biassette H, Lehmann Che J, et al. IDH-Mutation Is a Weak Predictor of Long-Term Survival in Glioblastoma Patients. PLoS ONE. 2015;10:e0130596 pubmed publisher
Kim J, Cho H, Xu W, Kim J, Kim S, Kim S, et al. Mechanism for enhanced 5-aminolevulinic acid fluorescence in isocitrate dehydrogenase 1 mutant malignant gliomas. Oncotarget. 2015;6:20266-77 pubmed
Mellai M, Piazzi A, Casalone C, Grifoni S, Melcarne A, Annovazzi L, et al. Astroblastoma: beside being a tumor entity, an occasional phenotype of astrocytic gliomas?. Onco Targets Ther. 2015;8:451-60 pubmed publisher
Hassler M, Vedadinejad M, Flechl B, Haberler C, Preusser M, Hainfellner J, et al. Response to imatinib as a function of target kinase expression in recurrent glioblastoma. Springerplus. 2014;3:111 pubmed publisher
Reuss D, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 2015;129:133-46 pubmed publisher
Libard S, Popova S, Amini R, Kärjä V, Pietiläinen T, Hämäläinen K, et al. Human cytomegalovirus tegument protein pp65 is detected in all intra- and extra-axial brain tumours independent of the tumour type or grade. PLoS ONE. 2014;9:e108861 pubmed publisher
Bodi I, Curran O, Selway R, Elwes R, Burrone J, Laxton R, et al. Two cases of multinodular and vacuolating neuronal tumour. Acta Neuropathol Commun. 2014;2:7 pubmed publisher
Popova S, Bergqvist M, Dimberg A, Edqvist P, Ekman S, Hesselager G, et al. Subtyping of gliomas of various WHO grades by the application of immunohistochemistry. Histopathology. 2014;64:365-79 pubmed publisher
Turcan S, Fabius A, Borodovsky A, Pedraza A, Brennan C, Huse J, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 2013;4:1729-36 pubmed
Korkolopoulou P, Levidou G, El Habr E, Adamopoulos C, Fragkou P, Boviatsis E, et al. Sox11 expression in astrocytic gliomas: correlation with nestin/c-Met/IDH1-R132H expression phenotypes, p-Stat-3 and survival. Br J Cancer. 2013;108:2142-52 pubmed publisher
Klink B, Miletic H, Stieber D, Huszthy P, Campos Valenzuela J, Valenzuela J, et al. A novel, diffusely infiltrative xenograft model of human anaplastic oligodendroglioma with mutations in FUBP1, CIC, and IDH1. PLoS ONE. 2013;8:e59773 pubmed publisher
Popov S, Jury A, Laxton R, Doey L, Kandasamy N, Al Sarraj S, et al. IDH1-associated primary glioblastoma in young adults displays differential patterns of tumour and vascular morphology. PLoS ONE. 2013;8:e56328 pubmed publisher
van den Bent M, Hartmann C, Preusser M, Strobel T, Dubbink H, Kros J, et al. Interlaboratory comparison of IDH mutation detection. J Neurooncol. 2013;112:173-8 pubmed publisher
Orr B, Haffner M, Nelson W, Yegnasubramanian S, Eberhart C. Decreased 5-hydroxymethylcytosine is associated with neural progenitor phenotype in normal brain and shorter survival in malignant glioma. PLoS ONE. 2012;7:e41036 pubmed publisher
Preusser M, Capper D, Hartmann C. IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee. Clin Neuropathol. 2011;30:217-30 pubmed
Capper D, Weissert S, Balss J, Habel A, Meyer J, Jäger D, et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 2010;20:245-54 pubmed publisher
Capper D, Zentgraf H, Balss J, Hartmann C, von Deimling A. Monoclonal antibody specific for IDH1 R132H mutation. Acta Neuropathol. 2009;118:599-601 pubmed publisher
image
image 1 :
Dianova DIA-H09 image 1
Infiltration zone of anaplastic astrocytoma with specific labelling of infiltrating glioma cells by antibody clone H09.
image 2 :
Dianova DIA-H09 image 2
Identification of single tumor cells in white matter distant from tumor center with antibody clone H09.
image 3 :
Dianova DIA-H09 image 3
Strong reaction of antibody clone H09 with IDH1 R132H mutated diffuse astrocytoma (left) but not with wild type tumor (right).
product information
Catalog Number :
DIA-H09
Product Name :
Anti-IDH1 R132H (Hu) from Mouse (Clone: H09)
Product Type :
Antibody
Host Species :
Mouse
Clonality :
Monoclonal
Conjugation :
nonconjugated
Clone Name :
H09
Isotype :
IgG2a
Size :
500 µl
List Price :
482 EUR plus VAT
Product Description :
Antibody clone H09 reacts specifically with the isocitrate dehydrogenase 1 (IDH1) R132H point mutation in tissue sections from formalin-fixed brain tumor.
Background :
Heterozygous point mutations of IDH1 codon 132 are frequent in World Health Organization (WHO) grade II and III gliomas. IDH1 R132H mutations occur in approximately 70% of astrocytomas and oligodendroglial tumors. The high frequency and distribution of the IDH1 R132H mutation among specific brain tumor entities allow the highly sensitive and specific discrimination of various tumors by immunohistochemistry, such as anaplastic astrocytoma from primary glioblastoma or diffuse astrocytoma WHO grade II from pilocytic astrocytoma or ependymoma. Noteworthy is the discrimination of the infiltrating edge of tumors with IDH1 mutation from reactive gliosis.
ALTnames :
Isocitrate dehydrogenase-1
Immunogen :
Synthetic peptide
Localization :
Cytoplasmic
Specificity :
Human IDH1 R132H point mutation
Purity :
Purified
Preservative :
0.05% NaN3
Concentration :
0.1 mg/ml
Application Summary :
IHC-P;WB
more info or order :
Dianova product webpage
company information
Dianova
Warburgstr. 45
D-20354 Hamburg
info@dianova.de
http://www.dianova.de
49 40 45 06 73 30
headquarters: Germany
Since its foundation in 1982, dianova GmbH provides professionals in Life Sciences with antibodies, immunoassays, and products for molecular biology. More than 30 years of grown expertise give rise to a fundamental knowledge about biochemical applications and a profound understanding of customer needs in research and routine diagnostic laboratories of universities, hospitals and the pharmaceutical industry.
Since its foundation in 1982, dianova GmbH provides professionals in Life Sciences with antibodies, immunoassays, and products for molecular biology. More than 30 years of grown expertise give rise to a fundamental knowledge about biochemical applications and a profound understanding of customer needs in research and routine diagnostic laboratories of universities, hospitals and the pharmaceutical industry.
In addition to distributing Life Science and Diagnostic Products in the German speaking region dianova manufactures and markets a series of antibodies with unique properties on a worldwide basis under the brand of optistain. To this end dianova has successfully established a distribution network in more than 25 countries.
At dianova quality is of paramount importance and subject to strict control. Internal controls and audits are carried out in addition to on-site inspections by independent, external inspection companies. In 2003 the TÜV Rheinland/Berlin/Brandenburg successfully completed the first comprehensive certification process. Since then dianova has been certified pursuant to the international DIN EN ISO 9001:2008 standard.